Moreover, there is preclinical evidence showing that PARP-1 inhibitors would be beneficial in acute diseases, such as stroke, traumatic brain injury, circulatory shock, and acute myocardial infarction, as well as in chronic diseases such as chronic heart failure and asthma (reviewed by Curtin) [67]. Here, PARP1 is linked to asthma.